A UK affilliate of Elliott Management has trimmed its stake in a Swiss pharmaceutical company whose shares have flagged as speculation about a possible sale waned. (view story)
Advertisements
Firm Profiles
-
- Amaranth Advisors
- Angelo, Gordon & Co.
- Appaloosa Management
- AQR Capital Management
- Avenue Capital Management
- Baupost Group
- BlueCrest Capital Management
- Brevan Howard Asset Management
- Bridgewater Associates
- Canyon Capital Advisors
- Caxton Associates
- Centerbridge Partners
- Cerberus Capital Management
- Citadel Advisors
- Clinton Group
- D. E. Shaw & Co.
- D.B. Zwirn & Co.
- Davidson Kempner Capital Management
- Duquesne Capital Management
- Ellington Financial Management
- Elliott Management
- ESL Investments
- Eton Park Capital Management
- Farallon Capital Management
- Fir Tree Partners
- Fortress Investment Group
- FrontPoint Partners
- Galleon Group
- GLG Partners
- GoldenTree Asset Management
- Greenlight Capital
- Harbinger Capital Partners
- HBK Capital Management
- Highbridge Capital Management
- Highfields Capital Management
- Highland Capital Management
- Icahn Capital
- King Street Capital Management
- Kingdon Capital Management
- Kynikos Associates
- Lone Pine Capital
- Long-Term Capital Management
- Marathon Asset Management
- Maverick Capital
- Millennium Management
- Moore Capital Management
- Oak Hill Advisors
- Oaktree Capital Management
- Och-Ziff Capital Management
- Omega Advisors
- Paulson & Co.
- Perry Capital
- Pershing Square Capital Management
- Plainfield Asset Management
- RAB Capital
- Renaissance Technologies
- S.A.C. Capital Advisors
- Satellite Asset Management
- Shumway Capital Partners
- Silver Point Capital
- Soros Fund Management
- Stark Investments
- Steinhardt Partners
- Third Point
- Tiger Management
- TPG-Axon Capital Management
- Trian Fund Management
- Tudor Investment
- Viking Global Investors
- York Capital Management
-
Advertisements
